1. Neoadjuvant rectal (NAR) score: Value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery?
- Author
-
Klara Hammarström, Israa Imam, Tobias Sjöblom, and Bengt Glimelius
- Subjects
medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Rectal cancer ,NAR-score ,Neoadjuvant therapy ,Neoplasm Staging ,Cancer och onkologi ,Chemotherapy ,Radiotherapy ,Rectal Neoplasms ,Surrogate endpoint ,business.industry ,Kirurgi ,Rectum ,Chemoradiotherapy ,Hematology ,Prognosis ,medicine.disease ,Neoadjuvant Therapy ,Surgery ,Radiation therapy ,Clinical trial ,Neoadjuvant Rectal Score ,Cell killing ,Oncology ,Cancer and Oncology ,030220 oncology & carcinogenesis ,Neoplasm Recurrence, Local ,business - Abstract
Introduction: The Neoadjuvant rectal (NAR) score is a new surrogate endpoint to be used in clinical trials for early determination of treatment response to different preoperative therapies. The aim is to further validate the NAR-score, primarily developed using chemoradiotherapy (CRT) with a delay to surgery 6-8 weeks, and explore its value using other schedules. Materials and Methods: The study included all 9978 patients diagnosed with non-metastasized RC in 2007-2015 that had undergone surgery and was registered in the Swedish Colorectal Cancer Registry. The patients of interest had either short-course radiotherapy (scRT)/CRT + delayed surgery, longcourse radiotherapy (RT) + delayed surgery, (C)RT + additional chemotherapy, primary surgery, or scRT + immediate surgery. The scRT/CRT + delayed surgery groups were further divided based on time to surgery. Results: Mean NAR-score differed significantly (p < 0.0001) between different treatments. (C) RT + additional chemotherapy had the lowest mean score of 16.3 and CRT + delayed surgery had 17.7. There was a significant difference (p < 0.05) in overall survival (OS) and time to recurrence (TTR) of patients with a Low NAR-score (16) for both CRT- and scRT, with a stronger correlation for CRT-patients. C-index for the NAR-score model (0.623) was not superior to when only pathological T- and N-stage was used (0.646). Conclusions: The NAR-score is prognostic, but it is not better than pT- and pN-stage. However, the NARscore can still discriminate between two treatments that have different cell killing effect and may still be of value in clinical trials as an easier method than pT- and N-stage.
- Published
- 2021